NCT04596839View on ClinicalTrials.gov

Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Covid19
Interventions
DRUG

Remdesivir

Remdesivir INN 100 mg lyophilized powder for infusion

OTHER

Standard of Care

Standard of Care Treatment for COVID-19 Infection

Trial Locations (1)

1206

Combined Military Hospital, Dhaka

All Listed Sponsors
lead

Dr. Md. Alimur Reza

INDUSTRY

NCT04596839 - Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19) | Biotech Hunter | Biotech Hunter